Sunshine Biopharma (Sunshine Biopharma) Interest Expense : $-0.15 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Sunshine Biopharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sunshine Biopharma's interest expense for the three months ended in Mar. 2024 was $ -0.05 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.15 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sunshine Biopharma's Operating Income for the three months ended in Mar. 2024 was $ -1.35 Mil. Sunshine Biopharma's Interest Expense for the three months ended in Mar. 2024 was $ -0.05 Mil. Sunshine Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sunshine Biopharma Interest Expense Historical Data

The historical data trend for Sunshine Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Interest Expense Chart

Sunshine Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.12

-0.17

-0.33

-0.04

-0.14

Sunshine Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.04	-0.03	-0.04	-0.03	-0.05

Sunshine Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15 Mil.

Sunshine Biopharma (NAS:SBFMW) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sunshine Biopharma's Interest Expense for the three months ended in Mar. 2024 was $-0.05 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-1.35 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.50 Mil.

Sunshine Biopharma's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Sunshine Biopharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Sunshine Biopharma (Sunshine Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFMW) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SBFM:USA

Address

6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5

Website

https://www.sunshinebiopharma.com

Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).